_pennystock版 - 【药股】More Buyouts In Biotech? (AUXL, HGSI, VRTX) |
|---|
|
|
|
|
|
g******0
发帖数: 1165 | 1 May 10, 2010 · Filed Under M&A, analyst calls
Everyone is looking for the next or the next to the next biotech and
BioHealth merger candidate. Just a day after being worried about major
financial losses all over again…. Morningstar has listed this week three
of its favorite buyout targets in biotech from its pool of large
pharmaceuticals, devices, instruments, and services companies.
Those are Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Human Genome
Sciences Inc. (NASDAQ: HGSI), and Vertex Pharmaceuticals Incorporated (
NASDAQ: VRTX). While we have a brief synopsis here in the image from
Morningstar, the full article goes into more detail.
Of the three merger candidates here, Human Genome Sciences (HGSI) seems the
biggest risk because its shares could have been acquired for far cheaper
when it was weak and chasing it now would perhaps only make sense for its
existing drup partner companies.
JON C. OGG | g******0
发帖数: 1165 | 2 【 以下文字转载自 Stock 讨论区 】
发信人: jhsph07 (银杏), 信区: Stock
标 题: 大家看看这几个公司被买断的可能性怎么样？
发信站: BBS 未名空间站 (Fri May 7 09:41:43 2010, 美东)
ISIS － GENZ
ONXX － Bayer
HGSI － GSK
再加一个:
PLX － PFE | g******0
发帖数: 1165 | 3 发信人: gucci320 (Cigdog), 信区: pennystock
标 题: 转个老帖~潜在被收购的医药公司名单-（希望大家发现宝藏）
发信站: BBS 未名空间站 (Thu May 6 10:58:19 2010, 美东)
Posted: 3/13/10 09:32
I will list all these targets mentioned by news:
Their top five candidates, based on their takeout target rankings, include
Vertex Pharmaceuticals (VRTX), as the Massachusetts-based company is close
to commercializing telaprevir, a potential blockbuster treatment for
hepatitis C.
“The company is building a diversified portfolio,” says Migliore. “The
company has no drugs on the market, and it has never been profitable. But it
has an $8 billion market cap because investors are so excited about its
lead drug candidate.”
The Morningstar team also likes Auxilium Pharma (AUXL). Its drug Xiaflex is
nearing the market for two rare conditions, says Migliore, which would
significantly boost the company’s profit potential.
A third potential target for investors to keep their eyes on: Human Genome
Sciences (HGSI), which moved up from number 32 on the 2009 list given the
impressive data for lupus drug Benlysta.
A fourth: InterMune, (ITMN), whose lead product candidate, pirfenidone,
could reach the market in 2010.
The fifth candidate is Celgene (CELG), which is the leader in blood-related
cancer treatments. | L********3
发帖数: 2272 | 4 是不是现在可以先买点存着
【在 g******0 的大作中提到】
: May 10, 2010 · Filed Under M&A, analyst calls
: Everyone is looking for the next or the next to the next biotech and
: BioHealth merger candidate. Just a day after being worried about major
: financial losses all over again…. Morningstar has listed this week three
: of its favorite buyout targets in biotech from its pool of large
: pharmaceuticals, devices, instruments, and services companies.
: Those are Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Human Genome
: Sciences Inc. (NASDAQ: HGSI), and Vertex Pharmaceuticals Incorporated (
: NASDAQ: VRTX). While we have a brief synopsis here in the image from
: Morningstar, the full article goes into more detail.
|
|
|
|
|
|
|
